An MHC-linked locus modulates thymic differentiation of CD4+CD25+Foxp3+ regulatory T lymphocytes

Julie Tellier1, Joost P. M. van Meerwijk1,2 and Paola Romagnoli1

1Tolerance and Autoimmunity section, Centre de Physiopathologie de Toulouse Purpan, Institut National de la Santé et de la Recherche Médicale (INSERM) U563; University Paul Sabatier and IFR 30, Institut Claude de Preval, Toulouse, France
2Institut Universitaire de France and Faculty of life-sciences (UFR-SVT), University Paul Sabatier, Toulouse, France

Keywords: T cells, thymus, tolerance

Abstract

CD4+CD25+Foxp3+ regulatory T lymphocytes are crucial for maintenance of immunological tolerance to self and innocuous non-self, are known to modulate immunity to tumors and infectious agents and can induce transplantation tolerance. Surprisingly, only a single genetic polymorphism is known to modulate regulatory T cell (Treg) development in the thymus, leading to a lethal autoimmune disorder. Here, we show that considerably different levels of Tregs are found in the thymi of distinct common laboratory mouse strains. We demonstrate that distinct levels of phenotypically and functionally identical Tregs develop with similar kinetics in the studied mice, that the responsible locus acts in a thymocyte-intrinsic manner and that levels of thymic Foxp3+ Tregs correlate to those found in the periphery. Using several congenic mouse strains, we mapped one of the at least two genetic loci capable of quantitatively modulating thymic Treg development to a ≈2.2 Mb region telomeric to the MHC. Our data indicate that polymorphic genes closely linked to the MHC locus substantially modulate differentiation of Tregs. Identification of responsible genes should help in understanding the mechanisms involved in commitment to the Treg lineage as well as selection of these cells in the thymus.

Introduction

Among the several mechanisms assuring T lymphocyte tolerance to self, CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a central and crucial role. Absence of these cells in experimental or clinical settings causes severe autoimmunity, and eventually may lead to death. Tregs do not only inhibit autoimmunity but also inhibit or fine regulate immunity to tumors and infection, and prevent inflammatory bowel disease in mice. These cells are also involved in transplantation tolerance; they can inhibit graft-versus-host disease as well as allograft rejection (1–6).

Given the potent immunomodulatory potential of Tregs, it is not very surprising that they have recently received a lot of attention. However, not a lot is known about their development. Tregs differentiate in the thymus (7) and MHC class II expression by cortical epithelial cells is sufficient for their positive selection (8). Deletion of autospecific Tregs can be induced by antigen-presenting cells of bone marrow origin (9, 10). These two features of thymic Tregs selection cannot explain their autoreactive repertoire (9, 11, 12). However, as compared with conventional T cell precursors, Treg precursors appear to be more resistant to deletion induced by epithelial cells (13–15). Moreover, in peripheral lymphoid organs, autospecific Tregs proliferate (11, 16–19). Therefore, differences in central Treg development as well as in peripheral homeostasis probably explain their autoreactive repertoire.

A very intriguing question in T cell development is how multipotent precursors commit to the different T cell lineages developing in the thymus. Again, little is known about Treg commitment. Based on the observation that significantly increased proportions of Treg develop in TCR/antigen doubly transgenic mice, it has been suggested that high-affinity MHC/peptide ligands can induce Treg commitment (20–23). However, it has recently been suggested that the increased percentages of CD4+CD8− (CD4SP) CD25+ thymocytes in

Received 1 December 2005, accepted 3 August 2006

Correspondence to: J. P. M. van Meerwijk; E-mail: joost.van-meerwijk@toulouse.inserm.fr

Transmitting editor: E. Vivier

Advance Access publication 30 August 2006
TCR/ligand doubly transgenic mice are not due to increased positive selection of Treg, but rather to deletion of CD4SP CD25+ (but not CD25high) thymocytes upon encounter of agonist ligand on thymic epithelial cells (13). The latter hypothesis, however, cannot explain our recent observation that in hematopoietic chimeras in which superantigens are exclusively presented by radioresistant thymic epithelial cells, substantially increased positive selection of superantigen-specific Foxp3+ Treg occurs (15). The data presented in the latter report support the view that agonist ligands enhance positive selection, rather than redirecting thymic precursors to the Treg lineage.

The question as to how precursor thymocytes commit to the Treg lineage remains therefore unanswered. Knowledge on genetic polymorphisms leading to differences in thymic Treg development could contribute to our understanding of Treg commitment as well as of selection of these cells in the thymus.

Differences in Treg development may also modulate susceptibility to autoimmunity, cancer and inflammatory bowel disease, and may even influence development of immunological memory. Despite these important considerations, only a single genetic polymorphism modulating thymic Treg development has been identified thus far. Mutations in the gene encoding the forkhead/winged helix transcription factor Foxp3, located on the X-chromosome, lead to a complete absence of CD4+CD25+ Treg development in mice (24–26). Foxp3 inactivation leads to a rapid death of affected males in the mouse and to the autoimmune disease immunodysregulation, polyendocrinopathy, enteropathy, X linked in man (27–29). Forced expression of Foxp3 in mouse or human CD25- T cells endows these cells with regulatory capacity (24–26, 30). Moreover, CD4+CD25+ regulatory cells express Foxp3, and naturally occurring CD25–Foxp3+ T cells have regulatory capacity (31). Therefore, Foxp3 is clearly a master switch in Treg development. However, the precise mechanisms leading to induction of Foxp3 expression during Treg development remain unclear.

We have recently described that Treg development is quantitatively controlled by as yet unidentified genetic factors. In distinct strains of common laboratory mice, we found small but statistically significant differences in thymic development of CD4SP CD25high Tregs (32). Here, we show that genes linked to the MHC very substantially modulate differentiation of mature Treg from their immature precursors. We mapped the responsible locus to a ~2.2 Mb region telomeric to the MHC. Ultimate identification of responsible genes should lead to a better understanding of Treg commitment, selection and potential function.

**Methods**

**Mice**
All mice were females of 5–7 weeks of age. C57BL/6N (B6), CBA, BALB/c, C3H, (B6 × DBA/2)F1 (B6D2F1) and (B6 × CBA)F1 (B6CBAF1) mice were purchased from Janvier (Le Genest St Isle, France), C57BL/10 (B10), B10.BR, BALB.K, B10.A, B10.A(2R) and AKR strains from Harlan France (Gannat, France) and C57BR animals from Jackson Laboratories (Bar Harbor, MN, USA). B6 Thy1.1 and (B6 × B10.BR)F1 mice were raised in our animal facilities. MHC (β2m and I-Aβ)-deficient B6 mice were bred in our facilities and originally obtained from CDTA (Orléans, France). For a description of the genotypes of B10.A and B10.A(2R) mice, see the following web site: http://imgt.cines.fr/textes/IMGTRepertoireMHC/Polymorphism/haplotypes/mouse/MHC/Mu_haplotypes.html. All experiments involving animals were performed in compliance with the relevant laws and institutional guidelines (INSERM; approval # 31-13, ethical review # MP/02/32/10/03).

**Antibodies**
The following antibodies and secondary reagents were used for phenotypic analysis: FITC-, PE-Cy7-, Pacific Blue- or allophycocyanin (APC)-labeled anti-CD4 ( GK1.5), FITC-, Alexa Fluor 700- or APC-labeled anti-CD8 (53.6.7), PE- or APC-labeled anti-CD25 (PC61), anti-HSA–FITC ( M1/69), anti-CD69–FITC (H1.2F3), anti-TCR–FITC (H35), anti-Thy1.1–FITC (HI31), biotin- or APC-labeled anti-Thy1.2 (53-2-1), anti-Foxp3–PE (FJ-16s) and PE-Cy5.5-labeled streptavidin (eBioscience, San Diego, CA, USA). Biotin-conjugated anti-glucocorticoid-induced TNF receptor (GITR) was purchased from R&D (Lille, France).

**Bone marrow chimeras**
Bone marrow from femurs and tibias was collected in DMEM medium supplemented with 10% FCS. Thy1-expressing cells were eliminated using AT83 (anti-Thy1.1) or HO.22.1.1 (anti-Thy1.1) culture supernatants and rabbit complement (Saxon, HD supplies, Aylesbury, Bucks, UK). Cells from each donor were injected intravenously into lethally γ-irradiated hosts (8.5 Gy; 137Cs source, 6.3 Gy per min) that were kept on antibiotic-containing water (0.2% of bacitracin; Roche, Basel, Switzerland) for the complete duration of the experiment (6 weeks).

**Flow cytometry**
Thymocytes, splenocytes or lymph node cells were incubated 30 min on ice in 2.4G2 (anti-FcγRI mAb) hybridoma supernatant also containing 10 μg ml−1 of milG. Cells were then incubated 20 min with saturating concentrations of antibodies. Labeled cells were analyzed using a FACSCalibur or an LSRII cytometer and CellQuest (BD Biosciences) or FlowJo (Tree Star, Ashland, OR, USA) software. Intracellular Foxp3 staining was performed according to the instructions of the supplier (eBioscience).

**BrdU incorporation studies**
For analysis of kinetics of thymic T cell development, mice were continuously exposed to the thymidine analogue bromodeoxyuridine (BrdU, 0.8 mg ml−1) in their drinking water for various times. Extracellular staining of thymocytes with mAbs against CD4, CD8 and CD25 was performed as described above. Cells were subsequently fixed, permeabilized and stained with FITC-labeled anti-BrdU antibody using the BrdU Flow Kit (BD Pharmingen, Heidelberg, Germany).

**Proliferation assays**
CD4+CD25+ and CD4+CD25− splenocytes were enriched as follows. Total splenocytes were treated with antibodies
(hybridoma culture supernatants) specific for CD8 (53.6.7), MHC class II (M5/114), FcγR (2.4G2), and thus targeted cells eliminated using anti-rat IgG-labeled Dynal beads (Dynal, Compiegne, France). Remaining cells were labeled with anti-CD25–PE antibody and subsequently with anti-PE-labeled microbeads, and CD25+ cells were positively selected on a magnetic column (Myltenyi, Paris, France). Remaining CD25− cells were labeled with anti-CD4–FITC, and CD4+ cells isolated by positive selection using anti-FITC-labeled microbeads. A purity of >97% was routinely obtained. CD4+ T cells (5±10^4) were cultured with titrated numbers of CD25+ cells and 5±10^4 irradiated MHC-deficient splenocytes in microtiter plates in the presence of soluble anti-CD3 antibody (2C11, 0.5µg mL^-1). [3H]Thymidine ([3H]TdR) was added 3 days later and 16 h later, cells were harvested and [3H]TdR incorporation measured.

Microsatellite markers and genotyping

Genomic DNA was prepared from tail tips using high pure PCR template preparation kit (Roche). Microsatellite markers are referenced in the Mouse Genome Database, release 3.5 (available from www.informatics.jax.org). PCR amplifications were performed in a T3 thermocycler (Biometra, Gottingen, Germany) in 20µl volumes using 100 ng genomic DNA, 0.2µM of each primer (Sigma-Proligo, The Woodlands, TX, USA), 1× PCR reaction buffer (Qbiogen, Illkirch, France), 0.5U Taq DNA polymerase, 3mM MgCl2, 0.2mM of each dNTP. The PCR products were size fractionated on 4% agarose gels (Resophor, Eurobio, Les Ulis, France) and visualized under UV light after staining with ethidium bromide.

Statistical analysis

Statistical significance of the data was analyzed using Student’s t-test. For correlation analysis, a two-tailed Spearman test was used. (*P < 0.05, **P < 0.01, ***P < 0.001, NS, non-significant).

Results

Considerable quantitative differences in the proportion of mature Tregs in the thymus of distinct inbred mouse strains

We have analyzed the percentage of Tregs among CD4SP TCR^high thymocytes in B6, C57BR, BALB/c, C3H, CBA, AKR and B10 mice (Fig. 1). Among CD4SP thymocytes, three levels of CD25 can be distinguished: negative, low and high (Fig. 1A). It has recently been shown that only CD25^high (but not CD25^int) cells uniformly express Foxp3 and have regulatory capacity (31, 33). We therefore calculated the percentage of CD25^high cells among CD4SP thymocytes. As shown in Fig. 1(B), we observed considerable differences between several of these inbred mouse strains.

A locus closely linked to the MHC controls Treg development in the thymus

We next investigated the potential implication of the MHC locus in the modulation of CD4SP CD25^high thymocyte development (Fig. 2). Congenic B10.BR mice carry the C57BR-derived MHC locus of H-2b haplotype on a B10 genetic background. Interestingly, these mice had as high levels of thymic CD4SP CD25^high cells as the C57BR donor strain (Fig. 2A), directly implicating an MHC-linked locus in the modulation of thymic Treg development. We next analyzed the proportion of CD25^high cells among CD4SP thymocytes in the congenic BALB.K strain, also carrying an MHC locus of H-2k haplotype, but on the BALB/c genetic background. Again, high levels of CD25^high cells were found among CD4SP thymocytes (Fig. 2A). Interestingly, the MHC locus carried by BALB.K mice is of C3H origin, and the latter strain actually has significantly lower percentages of CD25^high cells than BALB.K mice (Fig. 2A). This result indicates that the C3H-derived MHC locus contains a gene allowing for development of high numbers of Treg (in BALB.K mice), and that in C3H mice non-MHC-linked genes neutralize the Treg development-promoting effect of this locus.

Differences in the proportion of CD25^high CD4SP cells may be caused by differences in development of CD25+ or CD25^high cells. To distinguish between these two possibilities, we calculated the ratio of CD4SP CD25+ and CD25^high thymocytes to their CD4–CD8+ (DP) precursors. The higher...
Fig. 2. The locus responsible for the modulation of Treg development is closely linked to the MHC. (A) Thymocytes from indicated mouse strains were analyzed by four-color flow cytometry. Mean values (±SD) of the percentages of CD25^{high} cells among CD4SP TCR^{high} thymocytes are shown (n > 5). (B) Ratios of CD25^{high} (upper panels) or CD25^{low} (lower panels) CD4SP TCR^{high} to DP thymocytes in indicated mouse strains. Depicted are mean values ± SD (n > 5). (C) Thymocytes were analyzed by four-color flow cytometry. Mean values (±SD) of the percentages of CD25^{high} cells among CD4SP TCR^{high} thymocytes are shown (n = 5). **P < 0.01, ***P < 0.001, Student’s t-test.
percentages of thymic Treg in B10.BR versus B10 and BALB.K versus BALB/c mice corresponded to increased Treg/DP ratios, indicating increased differentiation of CD25^{high} cells from DP precursors (Fig. 2B). No differences were observed between the ratios of CD4SP CD25^- to DP thymocytes in the mouse strains analyzed (Fig. 2B). Combined, these results indicate that the MHC locus of H-2^b haplotype contains a gene (or genes) that significantly modulates Treg development.

MHC class II molecules are not responsible for the modulation of Treg development

Potential candidates for genes residing in the MHC locus and modulating thymic Treg development are the MHC class II genes, which are required for Treg differentiation. The potential implication of MHC class II genes was assessed in two different manners.

We first analyzed recombinant congenic mouse lines (Fig. 2C). B10.A mice express I-A and I-E molecules of H-2^b haplotype and, very interestingly, have high levels of thymic Tregs. However, B10.A(2R) mice, that express the same I-A^k and I-E^k molecules (34), have significantly lower percentages of CD25^{high} cells among CD4SP thymocytes. Therefore, the high levels of thymic Treg in B10.A mice are not due to expression of MHC class II molecules of H-2^k haplotype.

Secondly, we assessed if the genes responsible for modulation of thymic Treg development act in a thymocyte-intrinsic or -extrinsic manner (Fig. 3). To this end, we generated radiation bone marrow chimeras by reconstituting H-2^k hosts with a mixture of B6.Thy1.1 and C57BR (Thy1.2) bone marrow. Six weeks later, thymocytes were analyzed by flow cytometry using the Thy1 allelic marker to distinguish between the two types of donor cells. In these chimeras, in which B6 and C57BR thymocytes developed in an identical thymic microenvironment, significantly more CD25^{high} cells developed from C57BR than from B6 precursors (Fig. 3A). Similar results were obtained with single and mixed bone marrow chimeras, made using B10.BR and B6 bone marrow (Fig. 3B). These results show that thymocyte-intrinsic factors considerably modulate thymic Treg development. They therefore confirm that MHC class II molecules are not responsible for the distinct percentages of mature thymic Treg observed in the mouse strains studied.

A genetic locus responsible for the modulation of thymic Treg development is located in a <2.2 Mb region telomeric to the MHC

The data presented here show that an MHC-linked locus contains genes capable of modulating Treg development in the thymus. Our comparison of B10.A and B10.A(2R) congenic mice indicates that a responsible gene must be located in or near the telomeric region of the MHC (34). We wished to more precisely define this region and performed microsatellite analyses of several congenic mouse strains (Table 1). As reported previously, B10.A(2R) congenics had lost a telomeric part of the introgressed strain A region in B10.A mice. This region of interest (cf. Fig. 2C), delimited by D17Mit214 and 148, was included in the introgressed regions of B10.BR and BALB.K mice. These data suggest that the ‘high Treg’ phenotype of B10.A, B10.BR and BALB.K mice may be due to the same genes.

We have previously published that Treg development is also quantitatively modulated by non-MHC-linked loci (32). In B10.S and B10.D2 congenic strains, decisive genes are located outside the introgressed donor regions. To define if the locus identified in the present report is distinct from those non-MHC-linked regions, we performed microsatellite analysis of part of chromosome 17 from B10.S and B10.D2 mice (Table 1).
B10.S and B10.D2 mice, which have a B10 'low Treg' phenotype (32), have donor (SJL and DBA/2, respectively) strain-derived D17Mit214 to 148 locus. Moreover, the introgressed DBA/2 region in B10.D2 mice completely overlaps the introgressed C3H region in BALB.K mice. These data unequivocally demonstrate that the genetic loci responsible for the quantitative thymic Treg phenotypes reported here and in our previous publication (32) are, at least in part, different.

**Distinct levels of thymic Tregs are caused by differences in their intrathymic differentiation**

Upon their differentiation, fully mature CD25^+ and CD25^- CD4SP thymocytes remain in the thymus for ~2 weeks (35, data not shown). Higher levels of CD25^{high} thymocytes may therefore be caused by prolonged retention time in the thymus or increased differentiation of these cells. To assess the latter possibility, we fed B6 and B10.BR mice with the nucleotide analog BrdU in their drinking water for various periods of time, and analyzed the appearance of BrdU-labeled Tregs (Fig. 4). More BrdU-^CD25^{high} cells were found among B10.BR than among B6 CD4SP thymocytes, while no difference was found for CD4SP CD25^- cells (Fig. 4). These data show that the difference in the proportion of CD25^{high} cells among CD4SP thymocytes is at least, in part, due to differences in their differentiation. However, formally we cannot exclude the possibility that a difference in thymic retention of Treg also plays a role.

### Table 1. Genetic characterization of congenic strains

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>D17mit164</td>
<td>3.89</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit171</td>
<td>6.98</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit57</td>
<td>8.5</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>BALB</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit114</td>
<td>11.06</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit79</td>
<td>11.24</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>BALB</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit133</td>
<td>22.66</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>DBA2</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit100</td>
<td>23.97</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>DBA2</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit229</td>
<td>28.53</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>BALB</td>
<td>B6</td>
<td></td>
</tr>
<tr>
<td>D17mit63</td>
<td>30.32</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>BALB</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit230</td>
<td>30.38</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>DBA2</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit16</td>
<td>31.30</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>C3H</td>
<td>DBA2</td>
<td></td>
</tr>
<tr>
<td>D17mit28</td>
<td>31.70</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>C3H</td>
<td>DBA2</td>
<td></td>
</tr>
<tr>
<td>D17mit231</td>
<td>32.23</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>C3H</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit34</td>
<td>32.44</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>C3H</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit32</td>
<td>32.45</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>C3H</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit214</td>
<td>32.94</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit233</td>
<td>33.66</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit47</td>
<td>33.97</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit125</td>
<td>34.25</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit24</td>
<td>35.26</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit234</td>
<td>36.83</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit176</td>
<td>40.25</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit36</td>
<td>44.33</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit250</td>
<td>44.98</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit177</td>
<td>46.08</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
<tr>
<td>D17mit66</td>
<td>50.14</td>
<td>BR</td>
<td>B6</td>
<td>B6</td>
<td>SJL</td>
<td>SJL</td>
<td></td>
</tr>
</tbody>
</table>

Physical distances (in megabases) were retrieved with the Ensembl browser (available from www.ensembl.org). Markers belonging to the chromosomal region introgressed into the recipient strains in congenic lines are in bold.

**Fig. 4.** Distinct levels of CD25^{high} Tregs differentiate in thymi of B6 and B10.BR mice. BrdU was administrated to mice in their drinking water continuously. Thymocytes were analyzed at indicated time points by four-color flow cytometry. Indicated are the percentages of CD25^{high}BrdU+ (left-hand panel) and CD25^-BrdU+ (right-hand panel) cells among CD4SP B6 and B10.BR (as indicated) thymocytes. *P < 0.05, **P < 0.01 (n = 3), Student’s t-test.
Regulatory T lymphocytes from low and high producer strains are phenotypically and functionally equivalent

We next investigated if the mature CD4SP CD25⁺ thymocytes developing in the distinct mouse strains were identical. Flow cytometry analysis revealed that the phenotype of mature Tregs in B6, B10.BR and C57BR mice was identical (Fig. 5A). HSA is expressed at high levels on immature thymocytes and down-modulated at the mature CD4SP stage of development. In contrast to their CD25⁻ and CD25⁺ counterparts, which are in majority HSA⁺ high, CD25⁺ CD4SP thymocytes all express relatively low levels of HSA. CD69 is an early activation marker that is up-regulated during thymic positive selection and down-modulated when thymocytes have reached the CD4SP stage of development. While most CD25⁻ and CD25⁺ CD4SP cells are CD69 high, practically all CD25⁺ CD4SP thymocytes are CD69 low. GITR is a marker highly expressed by Treg and at lower levels by conventional T lymphocytes. The phenotype of these three markers, allowing for a clear distinction between regulatory and conventional T cells, was identical for B6, B10.BR and C57BR CD25⁺ CD4SP thymocytes.

Probably the best marker for Treg is the transcription factor Foxp3 (24–26, 30, 31). We therefore also analyzed expression of this protein in B6 and B10.BR CD4SP thymocytes. As shown in Fig. 5B similar high levels of Foxp3 were observed in CD4SP CD25⁺ high thymocytes in these two mouse strains.

We next analyzed the immunomodulatory effector function of B6- and B10.BR-derived CD4⁺ CD25⁺ Foxp3⁺ T lymphocytes (Fig. 5C). Using an in vitro T cell proliferation inhibition assay, we observed that Tregs from the high and low producer strains B10.BR and B6, respectively, were similarly effective. Combined, these data show that the CD4⁺ CD25⁺ Foxp3⁺ cells developing in the distinct mouse strains analyzed represent genuine Tregs and not some other CD25⁺ population (e.g. activated conventional T cells).

Thymocyte-intrinsic factors modulate development of Foxp3⁺ Treg

Regulatory T lymphocytes are predominantly, but not exclusively, CD25⁺ high. The very best marker for Treg is Foxp3 and we therefore assessed if the genetic difference in Treg development holds true if these cells are defined as those expressing this transcription factor (Fig. 6). Mixed bone marrow chimeras were generated by reconstituting lethally irradiated hosts with a mixture of B6.Thy1.1 and B10.BR (Thy1.2) bone marrow. Six weeks later, thymocytes from these chimeras were analyzed using the allelic Thy1 marker to distinguish between the two types of donor bone marrow injected. As shown in Fig. 6, substantially more Foxp3⁺ CD4SP thymocytes were observed among B10.BR than among B6 thymocytes.

Since no markers are available to distinguish between BALB/c and BALB.K CD4SP thymocytes, we generated two types of bone marrow chimeras. Lethally irradiated hosts were reconstituted with B6.Thy1.1 plus BALB/c or BALB.K (Thy1.2) bone marrow. Thymocytes from these chimeras were analyzed six weeks later. In both types of chimeras, identical percentages of Foxp3⁺ CD4SP cells among B6 thymocytes were found (Fig. 6). BALB.K thymocytes contained substantially more Foxp3⁺ CD4SP Treg than BALB/c thymocytes.

These data show that development of Foxp3⁺ regulatory T lymphocytes is modulated by polymorphic genes linked to the MHC locus.

The percentages of thymic and peripheral Foxp3⁺ Treg in distinct mouse strains are directly correlated

We next investigated if the percentages of Foxp3⁺ CD4SP thymocytes are correlated to those found in lymph nodes and spleen. The percentages of CD4SP TCR high/Foxp3⁺ cells among CD4SP TCR high thymocytes, splenocytes and lymph node cells from B6 + B10.BR → B6CBAF1, B6 + BALB/c → B6D2F1 and B6 + BALB/K → B6CBAF1 mixed bone marrow chimeras were analyzed by flow cytometry. As shown in Fig. 7, a statistically significant correlation between thymic and peripheral levels of Foxp3⁺ cells was found. No statistically significant correlation between thymic and peripheral Treg was observed when Tregs were defined as CD25⁺ high cells (data not shown).

Discussion

In this report, we showed that genetic factors modulate thymic development of Tregs in a quantitatively very substantial fashion. Responsible genes act in a thymocyte-intrinsic manner and modulate the differentiation of Treg from their immature precursors. Importantly, we mapped the locus involved to a ≤2.2 Mb region telomeric to the MHC, definitively excluding a role for MHC class II genes.

Our data indicate that MHC-linked genes very substantially modulate thymic differentiation of CD4⁺CD25⁺Foxp3⁺ Tregs. We have previously reported that also non-MHC-linked loci modulate Treg development, although in a quantitatively much less impressive manner (32). Importantly, using microsatellite analysis of the precise donor regions introgressed into the distinct congenic mouse strains used in the present and our previously published reports, we here firmly establish that Treg development is quantitatively controlled by multiple loci. Interestingly, BALB.K mice have a high percentage of Tregs, in contrast to both the MHC donor (C3H) and acceptor (BALB/c) mouse strains. This observation indicates that (a) non-MHC-linked gene(s) inhibit(s) the Treg differentiation promoting activity of an MHC-linked gene in C3H mice, and again confirms that multiple genes modulate Treg development. Only a single other example for genetic control of Treg development is currently known. Mutations in the gene encoding the forkhead/winged helix transcription factor Foxp3 lead to a complete absence of CD4⁺CD25⁺ Treg development in mice. However, no subtler genetically controlled effects on Treg development were previously known.

At least three of the studied mouse strains (C3H, CBA and B10.BR) carrying an MHC-linked gene allowing for development of high numbers of Treg are reference models for experimental autoimmune thyroiditis (36, 37). Since levels of thymic and peripheral Foxp3⁺ Tregs are directly correlated, it is tempting to speculate that the responsible gene would somehow be involved in susceptibility to autoimmunity. However, C3H mice also carry another gene that inhibits expression of the thymic phenotype of the MHC-linked gene. Therefore, we do not think that the responsible gene would
Fig. 5. CD4+CD25^{high} Tregs from low and high producer strains are phenotypically and functionally identical. (A) Thymocytes from indicated mouse strains were analyzed by four-color flow cytometry. Electronically gated CD4SP cells were analyzed for expression of the indicated surface markers. (B) Electronically gated CD4SP thymocytes from indicated mouse strains were analyzed for CD25 and intracellular Foxp3 expression by flow cytometry. (C) CD4+CD25^{high} splenic conventional T cells (Teff) from B6 or B10.BR mice were stimulated with anti-CD3 antibody and MHC-deficient antigen-presenting cells in the presence of B6 (filled square) or B10.BR (open square) Treg at indicated ratios, and proliferation assessed by $[^{3}H]$Tdr incorporation. A representative of three independent experiments with similar results is shown.
affect susceptibility to autoimmune disease for simple quantitative reasons. Rather, since it acts in a Tcell intrinsic manner, the responsible gene could somehow influence peripheral function of Treg, for example by affecting TCR-repertoire, homing, adhesion or TCR-signal transduction. Identification of such differences will first require identification of the responsible genes and then generation and extensive analysis of genetically modified mice. It will also be of considerable interest to study Treg development in other mouse models for autoimmune disease.

Here we showed that percentages of thymic and peripheral Foxp3$^+$ Tregs were directly correlated. In contrast, levels of thymic and peripheral CD25$^+$ Tregs did not correlate. This observation is, at least in part, explained by our observation that substantial differences exist between the fraction of Foxp3$^+$ cells expressing high levels of CD25 in the thymus and the periphery (data not shown). CD25 expression by Treg has previously been shown to be unstable in vivo (38). It will be of interest to study the factors determining CD25 expression by Treg in vivo.

Identification of the responsible genes will also be important to study Treg development in the thymus. It is currently

---

**Fig. 6.** A thymocyte-intrinsic mechanism causes development of distinct proportions of Foxp3$^+$ Tregs. Lethally irradiated B6CBAF1 (H-2$^{b}$) or B6D2F1 (H-2$^{d}$) hosts ($n = 5$ for each) were reconstituted with a mixture of bone marrow cells at a ratio of 1:1 from B6.Thy1.1 and either B10 BR (Thy1.2), BALB/c (Thy1.2) or BALB.K (Thy1.2) mice. Six weeks later, thymocytes were analyzed by four-color flow cytometry for expression of CD4, CD8, Foxp3 (isotype matched control in gray shading), Thy1.1 and Thy1.2. Cells were electronically gated as indicated and the percentage of Foxp3$^+$ cells among CD4SP Thy1.1$^+$ or CD4SP Thy1.2$^+$ cells was calculated. Bar graphs depict mean values ($\pm$SD). ***$P < 0.001$, Student’s t-test.

**Fig. 7.** Direct correlation between levels of thymic and peripheral Foxp3$^+$ Tregs. Thymocytes, splenocytes and lymph node (LN) cells from the hematopoietic chimeras shown in Fig. 6 were stained with anti-CD4, anti-CD8, anti-Foxp3, anti-Thy1.1 and anti-Thy1.2 antibodies and analyzed by flow cytometry. The percentage of Foxp3$^+$ cells among CD4SP cells of B6 (open diamond), B10.BR (open square), BALB/c (open circle) or BALB.K (cross) origin was calculated. A statistically significant correlation (Spearman test) exists between thymocyte and splenocyte values ($P < 0.001$) on one hand (A), and thymocyte and LN cell ones ($P < 0.05$) on the other (B).
unknown how and when during development T cell precursors commit to the Foxp3+ Treg lineage. As discussed in Introduction, it remains unclear if high-affinity recognition of MHC/peptide ligands by immature precursors commits these cells to the Treg lineage (13, 15, 20–22). Identification of the genes involved in the quantitative modulation of Treg differentiation described here, and the processes in which they are involved, should open new avenues for the study of the still enigmatic process of Treg development.

Acknowledgements

We thank the staff of the IFR 30 animal facility, and in particular Maryline Calise, for expert animal husbandry. We also gratefully acknowledge Gilbert Fournié and Jean-Charles Guéry for critical reading of the manuscript.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>Allophycocyanin</td>
</tr>
<tr>
<td>BrdU</td>
<td>Bromodeoxyuridine</td>
</tr>
<tr>
<td>B6</td>
<td>C57BL/6</td>
</tr>
<tr>
<td>B10</td>
<td>C57BL/10</td>
</tr>
<tr>
<td>CD4SP</td>
<td>CD4+CD8</td>
</tr>
<tr>
<td>DP</td>
<td>CD4+CD8</td>
</tr>
<tr>
<td>GITR</td>
<td>Glucocorticoid-induced TNF receptor</td>
</tr>
<tr>
<td>[3H]TdR</td>
<td>[3H]Thymidine</td>
</tr>
<tr>
<td>Treg</td>
<td>Regulatory T cell</td>
</tr>
</tbody>
</table>

References


